Elon Musk Acknowledges Potential of Psychedelic Substances at CodeCon
During an interview at CodeCon 21, Elon Musk stated that individuals should be open to psychedelic substances. The tech-development event was hosted by Field Trip Health’s executive chairman, Ronan Levy, who asked Musk about whether he supported the use of psychedelic substances for therapeutic purposes.
Levy asked Musk about the role psychedelics could play in addressing some of the society’s destructive tendencies, with Musk replying that while most of individuals who were making laws currently were from a different era, there would be greater receptivity to the substances’ benefits as a new generation got into political power.
Field Trip Health is focused on the provision of psychedelic-assisted therapies. Toward the end of August, the company issued a press release announcing its new programs, which include one that allows qualified therapists to offer ketamine-assisted psychotherapy to their patients at the company’ centers. The therapists will be allowed to use the company’s medical teams for screening, prescribing and administration of ketamine.
In addition to this, the company’s programs will also offer experiential and didactic training to medical professionals and therapists on ketamine-assisted psychotherapy. Therapists who finish the company’s training programs will become eligible to join its ketamine-assisted psychotherapy co-op program.
This is not the first time the billionaire showed support for the use of psychedelics or cannabis. Last year, Musk tweeted a statement alluding to his use of DMT, which many believe was an admission that he’d tried the psychedelic.
A lot of weight is usually placed on his opinions, which is apparent in the way his comments influenced the value of Bitcoin and Dogecoin. Earlier in 2019, the billionaire smoked weed on High Times’ and the Joe Rogan Experience, which set off a lot of criticism. Soon after, the U.S. Securities and Exchange Commission sanctioned him and a petition urging Twitter to deplatform him began circulating.
In addition to this, unnamed sources reveal that NASA began a safety review of the billionaire’s SpaceX company shortly after his interview on the Joe Rogan Experience. Bob Jacobs, who is the NASA spokesman, didn’t reveal if the billionaire smoking a blunt was what prompted the review, but he did assert the importance of SpaceX adhering to the rules of a drug-free work environment.
All this occurred despite the fact that numerous studies have shown the therapeutic benefits of cannabis, which is known to possess various properties including anti-inflammatory, neuro-protective, analgesic and antispastic properties.
That Musk is speaking in support of psychedelics isn’t surprising given that companies such as Vancouver-based Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are seeing success administering ketamine treatments in clinical settings and also researching other psychedelic compounds with therapeutic potential.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
During an interview at CodeCon 21, Elon Musk stated that individuals should be open to psychedelic substances. The tech-development event was hosted by Field Trip Health’s executive chairman, Ronan Levy, who asked Musk about whether he supported the use of psychedelic substances for therapeutic purposes.
Levy asked Musk about the role psychedelics could play in addressing some of the society’s destructive tendencies, with Musk replying that while most of individuals who were making laws currently were from a different era, there would be greater receptivity to the substances’ benefits as a new generation got into political power.
Field Trip Health is focused on the provision of psychedelic-assisted therapies. Toward the end of August, the company issued a press release announcing its new programs, which include one that allows qualified therapists to offer ketamine-assisted psychotherapy to their patients at the company’ centers. The therapists will be allowed to use the company’s medical teams for screening, prescribing and administration of ketamine.
In addition to this, the company’s programs will also offer experiential and didactic training to medical professionals and therapists on ketamine-assisted psychotherapy. Therapists who finish the company’s training programs will become eligible to join its ketamine-assisted psychotherapy co-op program.
This is not the first time the billionaire showed support for the use of psychedelics or cannabis. Last year, Musk tweeted a statement alluding to his use of DMT, which many believe was an admission that he’d tried the psychedelic.
A lot of weight is usually placed on his opinions, which is apparent in the way his comments influenced the value of Bitcoin and Dogecoin. Earlier in 2019, the billionaire smoked weed on High Times’ and the Joe Rogan Experience, which set off a lot of criticism. Soon after, the U.S. Securities and Exchange Commission sanctioned him and a petition urging Twitter to deplatform him began circulating.
In addition to this, unnamed sources reveal that NASA began a safety review of the billionaire’s SpaceX company shortly after his interview on the Joe Rogan Experience. Bob Jacobs, who is the NASA spokesman, didn’t reveal if the billionaire smoking a blunt was what prompted the review, but he did assert the importance of SpaceX adhering to the rules of a drug-free work environment.
All this occurred despite the fact that numerous studies have shown the therapeutic benefits of cannabis, which is known to possess various properties including anti-inflammatory, neuro-protective, analgesic and antispastic properties.
That Musk is speaking in support of psychedelics isn’t surprising given that companies such as Vancouver-based Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are seeing success administering ketamine treatments in clinical settings and also researching other psychedelic compounds with therapeutic potential.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
